<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39367688</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-9114</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Pharmacotherapy</Title><ISOAbbreviation>Pharmacotherapy</ISOAbbreviation></Journal><ArticleTitle>Intravenous ketamine successfully treats treatment-resistant catatonia in schizophrenia: A case report.</ArticleTitle><Pagination><StartPage>822</StartPage><EndPage>824</EndPage><MedlinePgn>822-824</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/phar.4612</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Benzodiazepines and electroconvulsive therapy (ECT) are mainstay treatments for catatonia, a potentially life-threatening psychomotor syndrome characterized by a range of symptoms, including immobility, mutism, stupor, posturing, and sometimes even agitation. It can be a manifestation of various underlying psychiatric or medical conditions, such as schizophrenia, mood disorders, or neurological disorders. When conventional treatments fail to alleviate symptoms, ketamine, a dissociative anesthetic, has emerged as a potential therapeutic option for catatonia. However, its precise mechanism of action in treating catatonia remains to be fully elucidated. The use of ketamine in treating treatment-resistant catatonia in patients with schizophrenia has not been described.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We describe a unique case of a 77-year-old female with schizophrenia for 15 years who presented with hallucinations, generalized weakness, immobility, stupor, and mutism consistent with severe catatonia. The electroencephalogram did not show seizures, and brain imaging was negative for stroke. Her catatonia was resistant to treatment with benzodiazepines and haloperidol. However, ECT was unavailable due to the COVID-19 pandemic. She was successfully treated with a single intravenous infusion of ketamine administered at a dose of 0.5 mg/kg over 40 min with complete rapid recovery and remained stable as an outpatient.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Intravenous ketamine single infusion may be a safe and feasible option in schizophrenia patients with drug-resistant catatonia, particularly in patients for whom standard therapies are ineffective. However, its use should be approached cautiously due to the risk of exacerbation of psychosis in patients with schizophrenia.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Further research is warranted to better understand the role of ketamine in the management of catatonia in this patient population.</AbstractText><CopyrightInformation>© 2024 Pharmacotherapy Publications, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Siddiqui</LastName><ForeName>Atif</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0004-3399-6163</Identifier><AffiliationInfo><Affiliation>Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pharmacotherapy</MedlineTA><NlmUniqueID>8111305</NlmUniqueID><ISSNLinking>0277-0008</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>690G0D6V8H</RegistryNumber><NameOfSubstance UI="D007649">Ketamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000778">Anesthetics, Dissociative</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007649" MajorTopicYN="Y">Ketamine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002389" MajorTopicYN="Y">Catatonia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090663" MajorTopicYN="N">Schizophrenia, Treatment-Resistant</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000778" MajorTopicYN="N">Anesthetics, Dissociative</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">catatonia</Keyword><Keyword MajorTopicYN="N">ketamine</Keyword><Keyword MajorTopicYN="N">schizophrenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>5</Day><Hour>11</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>5</Day><Hour>3</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39367688</ArticleId><ArticleId IdType="doi">10.1002/phar.4612</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry. 2015;172(10):950‐966.</Citation></Reference><Reference><Citation>Carroll BT. The universal field hypothesis of catatonia and neuroleptic malignant syndrome. CNS Spectr. 2000;5(7):26‐33.</Citation></Reference><Reference><Citation>Carroll BT, Goforth HW, Thomas C, et al. Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. J Neuropsychiatry Clin Neurosci. 2007;19(4):406‐412.</Citation></Reference><Reference><Citation>Northoff G, Eckert J, Fritze J. Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine. J Neurol Neurosurg Psychiatry. 1997;62(4):404‐406.</Citation></Reference><Reference><Citation>Tuerlings JH, van Waarde JA, Verwey B. A retrospective study of 34 catatonic patients: analysis of clinical care and treatment. Gen Hosp Psychiatry. 2010;32(6):631‐635.</Citation></Reference><Reference><Citation>Caroff SN, Mann SS, Francis A, et al. Catatonia From Psychopathology to Neurobiology. American Psychiatric Publishing; 2004.</Citation></Reference><Reference><Citation>Bush G, Fink M, Petrides G, et al. Catatonia. II. Treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand. 1996;93(2):137‐143.</Citation></Reference><Reference><Citation>Rogers JP, Pollak TA, Begum N, et al. Catatonia: demographic, clinical and laboratory associations. Psychol Med. 2021;53:2492‐2502.</Citation></Reference><Reference><Citation>Carroll BT, Thomas C, Jayanti K. Amantadine and memantine in catatonic schizophrenia. Ann Clin Psychiatry. 2006;18:131‐132.</Citation></Reference><Reference><Citation>Carpenter SS, Hatchett AD, Fuller MA. Catatonic schizophrenia and the use of memantine. Ann Pharmacother. 2006;40:344‐346.</Citation></Reference><Reference><Citation>Iserson K, Durga D. Catatonia‐like syndrome treated with low‐dose ketamine. J Emerg Med. 2020;58:771‐774.</Citation></Reference><Reference><Citation>Sarma S, Arunachalam A, Kamara M, Branjerdporn G. Ketamine as an alternative to ECT in Catatonia in elderly women with bipolar disorder: a case report. Front Psychiatry. 2023;14:1138772.</Citation></Reference><Reference><Citation>Kobayashi B, Wright C, Burns M, et al. Ketamine for acute catatonia: a case report. Curr Psychiatr Ther. 2021;20(6):24‐28.</Citation></Reference><Reference><Citation>Gregor E, Zheng W. Oral and intranasal ketamine use in treatment resistant catatonia: a clinical case report. Am J Case Rep. 2023;24:e939530‐1–e939530‐5.</Citation></Reference><Reference><Citation>Lahti A, Weiler M, Tamara M, Parwani A, Tamminga C. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 2001;25:455‐467.</Citation></Reference><Reference><Citation>Caliman‐Fontes AT, Vieira F, Leal GC, et al. Ketamine for catatonia: a novel treatment for an old clinical challenge? A systematic review of the evidence. Schizophr Res. 2024;271:355‐370. doi:10.1016/j.schres.2024.07.055</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>